For the 300mg dosing group, 61% (33 of 54) of patients receiving RSD1235 (oral) completed the study in normal heart rhythm, as compared to 43% (24 of 56) of all patients receiving placebo.
For the 600mg dosing group, 61% (30 of 49) of patients receiving RSD1235 (oral) completed the study in normal heart rhythm, as compared to 43% of all patients receiving placebo.
In both dosing groups, RSD1235 (oral) appeared safe and well-tolerated within the target population.
RSD1235 (oral) is under investigation as a chronic-use oral drug for the maintenance of normal heart rhythm following termination of atrial fibrillation (AF).
Find more details from the press release.
Comment Preview